Molecular Biosystems completes Oralex Phase I trials
This article was originally published in Clinica
Molecular Biosystems hopes to begin Phase II trials of its orally-administered abdominal ultrasound imaging agent, Oralex, this summer following completion of Phase I trials. The agent was more effective than water, the standard agent for this procedure, in displacing gas in the stomach and slowing the gastric emptying process, says MBI. The results are awaiting FDA review.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.